Literature DB >> 12105163

Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.

Kristian Wachtell1, Vittorio Palmieri, Michael H Olsen, Eva Gerdts, Vasilios Papademetriou, Markku S Nieminen, Gunnar Smith, Björn Dahlöf, Gerard P Aurigemma, Richard B Devereux.   

Abstract

BACKGROUND: We have shown that hypertensive patients with left ventricular (LV) hypertrophy have decreased LV midwall mechanics, but the effect of antihypertensive therapy remains unclear. METHODS AND
RESULTS: Echocardiograms were recorded at baseline in 679 hypertensive patients and ECG LV hypertrophy and repeated yearly during 3 years of blinded treatment to achieve target blood pressures (BPs) of 140/90 mm Hg. On average, BP was reduced from 174+/-21 to 147+/-19 over 95+/-11 to 82+/-10 mm Hg and LV mass from 234+/-56 to 194+/-50 g. Endocardial fractional shortening (FS) decreased slightly, whereas midwall FS increased from 15.4+/-2.0% to 16.8+/-2.1% and stress-corrected midwall FS increased from 97+/-13 to 105+/-12% (all P<0.001). Change in midwall FS was related inversely to change in LV mass (LVM), relative wall thickness (RWT), and diastolic BP and directly to change in Doppler stroke volume (SV, all P<0.001). Multivariate analysis showed that change in MWS was independently inversely related to changes in LVM (beta=-0.211), RWT (beta=-0.334, all P<0.001), and diastolic BP (beta=-0.088, P<0.05) and directly related to SV (beta=0.192, P<0.001) with control for blinded therapy. Change in stress-corrected midwall shortening was inversely independently associated with changes in LVM (beta=-0.153) and RWT (beta=-0.562) and directly with changes in SV (beta=0.145) and systolic BP (beta=0.s221, all P<0.001) with control for blinded therapy.
CONCLUSIONS: Antihypertensive therapy reduced LVM and increased LV midwall shortening and contractility with a small decrease in LV chamber function and significant increase in SV. Change in systolic LV performance was independently associated inversely with change in LVM, RWT, and BP and directly with change in SV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105163     DOI: 10.1161/01.cir.0000021601.49664.2a

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  Regression of left ventricular hypertrophy: are there preferred drugs?

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

Review 2.  Hypertension as a risk factor for heart failure.

Authors:  Arun Kannan; Rajesh Janardhanan
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

3.  Position Statement on Indications of Echocardiography in Adults - 2019.

Authors:  Silvio Henrique Barberato; Minna Moreira Dias Romano; Adenalva Lima de Souza Beck; Ana Clara Tude Rodrigues; André Luiz Cerqueira de Almeida; Bruna Morhy Borges Leal Assunção; Eliza de Almeida Gripp; Fabio Villaça Guimarães Filho; Henry Abensur; José Maria Del Castillo; Marcelo Haertel Miglioranza; Marcelo Luiz Campos Vieira; Márcio Vinicius Lins de Barros; Maria do Carmo Pereira Nunes; Maria Estefania Bosco Otto; Renato de Aguiar Hortegal; Rodrigo Bellio de Mattos Barretto; Thais Harada Campos; Vicente Nicoliello de Siqueira; Samira Saady Morhy
Journal:  Arq Bras Cardiol       Date:  2019-08-08       Impact factor: 2.000

4.  Complete reversal of hypertensive cardiomyopathy after initiating combined antihypertensive therapy.

Authors:  Marijn J Holl; Sweder W van de Poll; Michelle Michels
Journal:  BMJ Case Rep       Date:  2016-04-08

5.  Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study.

Authors:  Keita Noda; Munehito Ideishi; Eiichiro Tashiro; Yoshiyuki Nakashima; Mitsuhide Imamura; Masahiko Seki; Masanori Fujino; Toshimitsu Sou; Masaki Kohara; Hisashi Kanaya; Nishiki Saku; Ritsu Kamei; Misao Yamasaki; Hiroshi Sakai; Naoki Gondo; Keijiro Saku
Journal:  Curr Ther Res Clin Exp       Date:  2003-03

6.  Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.

Authors:  Scott L Hummel; E Mitchell Seymour; Robert D Brook; Samar S Sheth; Erina Ghosh; Simeng Zhu; Alan B Weder; Sándor J Kovács; Theodore J Kolias
Journal:  Circ Heart Fail       Date:  2013-08-28       Impact factor: 8.790

7.  Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats.

Authors:  Oscar H Cingolani; Xiao-Ping Yang; Yun-He Liu; Mirko Villanueva; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2004-03-15       Impact factor: 10.190

8.  Relationship Between Tei Index and PEP-Derived Myocardial Performance Index in Sinus Rhythm.

Authors:  Feyzullah Besli; Cengiz Basar; Ismail Ekinozu; Yasin Turker
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

9.  A Fortified Method to Screen and Detect Left Ventricular Hypertrophy in Asymptomatic Hypertensive Adults: A Korean Retrospective, Cross-Sectional Study.

Authors:  Hyo Eun Park; Sung-Bin Chon; Sang Hoon Na; Heesun Lee; Su-Yeon Choi
Journal:  Int J Hypertens       Date:  2018-11-25       Impact factor: 2.420

10.  Ultrasound and Microbubble-targeted Delivery of a microRNA Inhibitor to the Heart Suppresses Cardiac Hypertrophy and Preserves Cardiac Function.

Authors:  Jonathan A Kopechek; Charles F McTiernan; Xucai Chen; Jianhui Zhu; Maureen Mburu; Rafey Feroze; Daniel A Whitehurst; Linda Lavery; Jissy Cyriac; Flordeliza S Villanueva
Journal:  Theranostics       Date:  2019-09-21       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.